Kristina Burow has an estimated net worth of $469 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., Erasca, Inc., Verve Therapeutics, Inc., Prime Medicine, Inc., Rapport Therapeutics, Inc., Maze Therapeutics, Inc., Lyell Immunopharma, Inc., Seaport Therapeutics, Inc., DA32 Life Science Tech Acquisition Corp., Receptos, Inc., Neumora Therapeutics, Inc., Gossamer Bio, Inc., Scholar Rock Holding Corp, Vir Biotechnology, Inc., Beam Therapeutics Inc., Metacrine, Inc., Unity Biotechnology, Inc., Sienna Biopharmaceuticals, Inc., Boundless Bio, Inc., and Metsera, Inc..

2023 was Kristina Burow's most active year for acquiring shares with 33 total transactions. Kristina Burow's most active month to acquire stocks was the month of April. 2021 was Kristina Burow's most active year for disposing of shares, totalling 33 transactions. Kristina Burow's most active month to dispose stocks was the month of April. 2025 saw Kristina Burow paying a total of $54,999,963.00 for 30,980,556 shares, this is the most they've acquired in one year. In 2015 Kristina Burow cashed out on 1,420,308 shares for a total of $5,931,588.00, their largest year based on trade value.